Research graph
References from Belimumab prevention against organ damage over 8 years and safety up to 13 years: three pooled open-label, long-term extension SLE studies. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1016/s0140-6736(24)00398-2
10.1016/s0140-6736(24)00398-2 · External reference
B Cell Therapy in Systemic Lupus Erythematosus: From Rationale to Clinical Practice
10.3389/fmed.2020.00316 · 2020 · External reference
10.1093/rheumatology/kez516
10.1093/rheumatology/kez516 · External reference
10.1093/rheumatology/kez584
10.1093/rheumatology/kez584 · External reference
10.1093/rheumatology/kep062
10.1093/rheumatology/kep062 · External reference
Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort
10.1002/acr.20648 · 2012 · External reference
10.1002/art.34672
10.1002/art.34672 · External reference
10.1136/annrheumdis-2013-205171
10.1136/annrheumdis-2013-205171 · External reference
10.1136/ard-2023-224762
10.1136/ard-2023-224762 · External reference
2025 American College of Rheumatology (ACR) Guideline for the Treatment of Systemic Lupus Erythematosus
10.1002/acr.25690 · 2026 · External reference
10.1136/annrheumdis-2020-216924
10.1136/annrheumdis-2020-216924 · External reference
10.1002/art.1780390303
10.1002/art.1780390303 · External reference
Association between organ damage and mortality in systemic lupus erythematosus: a systematic review and meta-analysis
10.1136/bmjopen-2019-031850 · 2020 · External reference
10.1002/art.11299
10.1002/art.11299 · External reference
10.1002/art.23678
10.1002/art.23678 · External reference
10.1002/art.34400
10.1002/art.34400 · External reference
10.1177/09612033211028653
10.1177/09612033211028653 · External reference
10.1016/s0140-6736(10)61354-2
10.1016/s0140-6736(10)61354-2 · External reference
Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study
10.1002/art.40049 · 2017 · External reference
10.1136/annrheumdis-2017-211631
10.1136/annrheumdis-2017-211631 · External reference
Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus
10.1002/art.41900 · 2022 · External reference
10.1002/art.30613
10.1002/art.30613 · External reference
Unresolved reference
External reference
Clinical Outcomes of Patients with SLE Treated with Belimumab, Without Versus With Prior Immunosuppressant Use: a US Claims Database Study
10.1007/s40744-025-00774-6 · 2025 · External reference
Improved Health Outcomes in Patients with Systemic Lupus Erythematosus Following Early Belimumab Initiation Without Prior Immunosuppressant Use: A Real-World Descriptive Study
10.1007/s40744-024-00675-0 · 2024 · External reference
Comparative analysis of long-term organ damage in patients with systemic lupus erythematosus using belimumab versus standard therapy: a post hoc longitudinal study
10.1136/lupus-2020-000412 · 2020 · External reference
10.1093/rheumatology/kez279
10.1093/rheumatology/kez279 · External reference
Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States
10.1002/art.40439 · 2018 · External reference
10.1136/annrheumdis-2018-214043
10.1136/annrheumdis-2018-214043 · External reference
Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus
10.1002/art.40861 · 2019 · External reference
10.1177/0961203315625119
10.1177/0961203315625119 · External reference
10.1002/art.24699
10.1002/art.24699 · External reference
Patient-reported outcome measured by EQ-5D and influencing factors among patients of systemic lupus erythematosus in China: a multicentre cross-sectional study from CSTAR Registry
10.1136/bmjopen-2024-096989 · 2025 · External reference
Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach
10.1002/acr.24092 · 2020 · External reference
Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting
10.1002/art.41253 · 2020 · External reference
Hydroxychloroquine Dose per Ophthalmology Guidelines and the Risk of Systemic Lupus Erythematosus Flares
10.1001/jama.2022.13591 · 2022 · External reference
10.1093/rheumatology/keaa382
10.1093/rheumatology/keaa382 · External reference
Atherosclerosis in Systemic Lupus Erythematosus
10.1007/s11883-023-01149-4 · 2023 · External reference
Prevalence and target attainment of traditional cardiovascular risk factors in patients with systemic lupus erythematosus: a cross-sectional study including 3401 individuals from 24 countries
10.1016/s2665-9913(24)00090-0 · 2024 · External reference
Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial
10.1016/s2665-9913(20)30355-6 · 2021 · External reference
10.1177/0961203319860579
10.1177/0961203319860579 · External reference
10.29327/1716874.42-719
10.29327/1716874.42-719 · External reference
Cancer incidence and the influence of immunosuppressive agents in Korean patients with systemic lupus erythematosus: a retrospective cohort study
10.1186/s13075-025-03482-2 · 2025 · External reference
10.1136/lupus-2026-el.347
10.1136/lupus-2026-el.347 · External reference
10.1016/j.semarthrit.2019.06.017
10.1016/j.semarthrit.2019.06.017 · External reference
10.1177/0961203313477227
10.1177/0961203313477227 · External reference
Prevalence of depression and anxiety in systemic lupus erythematosus: a systematic review and meta-analysis
10.1186/s12888-017-1234-1 · 2017 · External reference
10.1093/mr/roag066
10.1093/mr/roag066 · External reference
Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison
10.1136/rmdopen-2021-001747 · 2021 · External reference
Safety of belimumab in adult patients with systemic lupus erythematosus: Results of a large integrated analysis of controlled clinical trial data
10.1177/09612033221131183 · 2022 · External reference
Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years
10.1136/rmdopen-2021-001669 · 2022 · External reference
Long-term safety and efficacy of belimumab in Japanese patients with SLE: A 7-year open-label continuation study
10.1093/mr/roab125 · 2023 · External reference
Postmarketing safety evaluation of belimumab: a pharmacovigilance analysis
10.1136/lupus-2024-001400 · 2025 · External reference
